2020 年第 3 期 第 15 卷

吉非替尼治疗非小细胞肺癌的效果分析及其机制研究

Effectiveness and mechanism of gefitinib in treatment of non-small cell lung cancer

作者：张丹牟尚东田姗李翔

英文作者：

单位：三二〇一医院肿瘤内二科，陕西省汉中市723000

英文单位：

关键词：非小细胞肺癌；吉非替尼；血管内皮生长因子；基质金属蛋白酶；成纤维细胞生长因子

英文关键词：

• 摘要：

• 【摘要】目的    分析吉非替尼治疗非小细胞肺癌的效果及其作用机制。方法    选取2012年1月至2016年1月三二〇一医院诊治的非小细胞肺癌患者140例。完全随机分为对照组和观察组，各70例。对照组患者接受吉西他滨联合顺铂治疗，观察组患者接受吉非替尼联合顺铂治疗。观察2组患者的临床治疗效果，检测治疗前后患者血清中血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）及基质金属蛋白酶（MMP）2和MMP-9水平变化。观察不良反应发生情况。结果    观察组总有效率明显高于对照组患者［50.0%（35/70）比42.9%（30/70）］，差异有统计学意义（χ2=3.903，P<0.001）。治疗前2组VEGF、bFGF、MMP-2、MMP-9水平差异均无统计学意义（均P>0.05）；治疗后2组以上指标均低于治疗前，且观察组低于对照组，差异均有统计学意义（均P<0.05）。观察组与对照组不良反应发生率差异无统计学意义［31.4%（22/70）比28.6%（20/70）］（χ2=0.982，P=0.152）。结论    吉非替尼对非小细胞肺癌有较好的治疗效果，可能与调节患者血清中VEGF和bFGF及MMP-2、MMP-9水平有关。

  
  

• 【Abstract】Objective    To analyze the effect of gefitinib on non-small cell lung cancer and the relevant mechanism. Methods    A total of 140 patients with non-small cell lung cancer were enrolled from January 2012 to January 2016 in 3201 Hospital. They were randomly divided into control group and observation group, with 70 cases in each group. The control group was treated with gemcitabine combined with cisplatin and the observation group was treated with gefitinib combined with cisplatin. Therapeutic effect, serum levels of vascular endothelial growth factor(VEGF), basicity fibroblast growth factor(bFGF)， matrix metalloproteinase(MMP)-2 amd MMP-9 were analyzed. Adverse reactions were observed. Results    Total effective rate in the observation group was significantly higher than that in the control group［50.0%（35/70） vs 42.9%（30/70）］(χ2=3.903, P<0.001). There were no significant differences in VEGF, bFGF, MMP-2 and MMP-9 levels between groups before treatment(all P>0.05). After treatment, these indexes significantly decreased and they were lower in the observation group than those in the control group(all P<0.05). There was no significant difference in the incidence of adverse reactions between groups［31.4%（22/70） vs 28.6%（20/70）］（χ2=0.982, P=0.152）. Conclusion    Gefitinib has a good therapeutic effect on non-small cell lung cancer through the regulation on serum levels of VEGF, bFGF, MMP-2 and MMP-9.